Smith & Nephew lowers 2026 sales outlook as US knee implant revenue falls 7%

Smith & Nephew announced a revision to its 2026 sales outlook, now expecting underlying revenue growth of about 4% versus the prior 6% target.

The change follows a second‑quarter report showing revenue of $1.6 billion, up 2.8% year‑over‑year, but underlying revenue fell 1.3% in the United States, driven by weakness in orthopedics and wound care.

U.S. knee‑implant sales were the biggest drag, dropping 7.2% as the company limited certain product placements and faced rising demand for cementless implants.

Smith & Nephew said new products, including a cementless version of its Landmark Knee System slated for launch in Q3 and broader adoption of its Legion MS system, should help revive the knee business.